Ascendis Pharma A/S (ASND)
| Market Cap | 15.74B |
| Revenue (ttm) | 1.20B +113.4% |
| Net Income | 847.43M |
| EPS | 13.38 |
| Shares Out | 65.67M |
| PE Ratio | 17.75 |
| Forward PE | 33.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 128,462 |
| Open | 239.09 |
| Previous Close | 237.59 |
| Day's Range | 236.00 - 240.69 |
| 52-Week Range | 203.80 - 282.15 |
| Beta | 0.49 |
| Analysts | Strong Buy |
| Price Target | 312.54 (+30.41%) |
| Earnings Date | Nov 11, 2026 |
About ASND
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing o... [Read more]
Financial Performance
In 2025, Ascendis Pharma's revenue was 720.13 million, an increase of 98.03% compared to the previous year's 363.64 million. Losses were -228.03 million, -39.69% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price target is $312.54, which is an increase of 30.41% from the latest price.
News
Ascendis Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Announced a $400 million share buyback and reaffirmed Vision 2030 goals of €5 billion in revenue, driven by three approved products and global expansion. Strong product launches, robust pipeline, and regained cardiometabolic rights support long-term growth, with no plans for new capital raises.
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple program...
Ascendis Announces Planned $400 Million Share Repurchase Program
COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of th...
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
COPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual...
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, ...
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with Bi...
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasi...
Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients
First patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal injecti...
Ascendis Pharma Earnings Call Transcript: Q2 2026
Q2 2026 saw product revenue more than double year-over-year to €315 million, driven by robust demand for YORVIPATH, SKYTROFA, and the U.S. launch of YUVIWEL. The company projects over €500 million in operating cash flow for 2026 and remains on track for its €5 billion 2030 revenue goal.
Ascendis Pharma Earnings release: Q2 2026
Ascendis Pharma released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Ascendis Pharma Reports Second Quarter 2026 Financial Results
– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH ® , €55 million for SKYTROFA ® , and €8 million for YUVIWEL ®
Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026
COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thur...
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided updates across its achondroplasia programs.
Ascendis Pharma Slides: Study update presentation
Ascendis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Ascendis Pharma Slides: Study result presentation
Ascendis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on July 8, 2026.
Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly T...
Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell...
Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its clinical development programs for the treatment of children with...
Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism
COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with T...
Ascendis Pharma Slides: Study result presentation
Ascendis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on June 13, 2026.
5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism
– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COP...
Ascendis Pharma Slides: Study result presentation
Ascendis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achon...